Sei Investments Co. Has $1.14 Million Holdings in Organon & Co. $OGN

Sei Investments Co. grew its holdings in Organon & Co. (NYSE:OGN) by 82.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 190,057 shares of the company’s stock after acquiring an additional 85,657 shares during the quarter. Sei Investments Co. owned 0.07% of Organon & Co. worth $1,139,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Organon & Co. by 2.7% in the 4th quarter. Vanguard Group Inc. now owns 36,916,382 shares of the company’s stock valued at $264,690,000 after purchasing an additional 987,979 shares during the period. State Street Corp increased its holdings in shares of Organon & Co. by 2.8% during the 4th quarter. State Street Corp now owns 9,597,761 shares of the company’s stock worth $68,816,000 after purchasing an additional 262,185 shares during the period. AQR Capital Management LLC raised its position in shares of Organon & Co. by 105.2% during the fourth quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock valued at $61,282,000 after buying an additional 4,394,814 shares during the last quarter. Private Management Group Inc. raised its position in shares of Organon & Co. by 38.3% during the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after buying an additional 1,204,979 shares during the last quarter. Finally, UBS Group AG lifted its stake in shares of Organon & Co. by 55.2% in the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after buying an additional 1,527,492 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Price Performance

NYSE:OGN opened at $13.66 on Thursday. The company has a 50-day moving average of $13.51 and a 200-day moving average of $10.68. The company has a market capitalization of $3.59 billion, a price-to-earnings ratio of 17.74, a PEG ratio of 1.26 and a beta of 1.55. Organon & Co. has a 52 week low of $5.69 and a 52 week high of $13.70. The company has a debt-to-equity ratio of 8.43, a quick ratio of 1.44 and a current ratio of 1.95.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Organon & Co.’s dividend payout ratio is 10.39%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and lifted their target price for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. Weiss Ratings downgraded Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Finally, BNP Paribas Exane reissued a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Five analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $11.40.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.